日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ticagrelor monotherapy versus ticagrelor plus aspirin in patients with chronic coronary syndrome and high ischaemic risk: a post hoc analysis of the TWILIGHT trial

替格瑞洛单药治疗与替格瑞洛联合阿司匹林治疗慢性冠状动脉综合征伴高缺血风险患者的疗效比较:TWILIGHT试验的事后分析

Gitto, Mauro; Baber, Usman; Sartori, Samantha; Vogel, Birgit; Angiolillo, Dominick J; Briguori, Carlo; Cohen, David J; Collier, Timothy; Dudek, Dariusz; Oliva, Angelo; Escaned, Javier; Feng, Yihan; Gibson, C Michael; Han, Ya-Ling; Di Muro, Francesca Maria; Shlofmitz, Richard A; Huber, Kurt; Steg, Philippe Gabriel; Sharma, Samin; Sardella, Gennaro; Kastrati, Adnan; Kaul, Upendra; Kornowski, Ran; Kunadian, Vijay; Stefanini, Giulio G; Mehta, Shamir R; Dangas, George; Mehran, Roxana

BLT-humanized C57BL/6 Rag2-/-γc-/-CD47-/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection

BLT 人源化 C57BL/6 Rag2-/-γc-/-CD47-/- 小鼠对 GVHD 具有抗性,并对 HIV 感染产生 B 细胞和 T 细胞免疫力

Kerry J Lavender, Wendy W Pang, Ronald J Messer, Amanda K Duley, Brent Race, Katie Phillips, Dana Scott, Karin E Peterson, Charles K Chan, Ulf Dittmer, Timothy Dudek, Todd M Allen, Irving L Weissman, Kim J Hasenkrug

Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein

编码 HSV-1 病毒宿主关闭蛋白的单纯疱疹病毒 2 dl5-29 疫苗候选株的构建和特性

Natalia J Reszka, Timothy Dudek, David M Knipe

Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes

单纯疱疹病毒 2 dl5-29 突变体中 U(L)41 基因的破坏增加了小鼠生殖器疱疹模型中的免疫原性和保护能力

Timothy Dudek, Lydia C Mathews, David M Knipe